Type 2 Diabetes Clinical Trial
Official title:
A Multicenter, Randomized, Prospective, Double-blind Study to Evaluate the Nephroprotective Effect of Delapril Alone or Combined With Manidipine in Patients With Type 2 Diabetes
Diabetes mellitus is one of the most common diseases globally, and is considered epidemic in many developed and newly industrialized nations. Diabetes mellitus represents the single largest cause of end-stage renal disease in the U.S. and Europe. At the same time, the primary cause of early death in diabetic patients are cardiovascular complications. Experimental and clinical studies found that angiotensin converting enzyme inhibitors (ACEi) and calcium channel blockers (CCBs) have a specific renoprotective effect and that this effect can be magnified when the two drugs are used in combination. To formally test this hypothesis we designed the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) study, a prospective, randomized, double blind trial aimed to compare the effect of 3 years treatment with the ACEi Delapril (30 mg/day), alone or combined to the CCB Manidipine (10 mg/day), versus conventional (non ACEi, non CCB) therapy on the rate of renal function loss and on the incidence of major cardiovascular events in 342 normo- and micro-albuminuric hypertensive type 2 diabetic patients.
INTRODUCTION Optimal blood pressure, glycemic and lipid control are of utmost importance to
minimize the incidence and the progression of chronic renal and cardiovascular complications
in patients with diabetes mellitus type 2. Whether angiotensin converting enzyme (ACE)
inhibitors alone or combined to calcium channel blockers (CCB) may further reduce the
incidence and progression of chronic complications is worth investigating.
AIMS The primary aim of this study is to assess whether at comparable levels of optimal
blood pressure and metabolic control, the ACE inhibitor delapril alone or in combination
with the dihydropyridine CCB manidipine slow the rate of glomerular filtration rate (GFR)
decline as compared with placebo plus conventional antihypertensive therapy in patients with
diabetes mellitus type 2 and hypertension. The secondary aim of this study is to assess the
effects of delapril and manidipine on the incidence of major cardiovascular events (acute
myocardial infarction, ictus or stroke, heart failure requiring hospitalization,
revascularization, amputation and cardiovascular mortality).
STUDY POPULATION 342 hypertensive type 2 diabetes patients with normo- or micro-albuminuria.
STUDY DESIGN This is a multicenter, prospective, randomized, double-blind,
placebo-controlled study. After a 12-week baseline period in which prohibited
antihypertensive treatments (ACE inhibitors, angiotensin II receptor antagonists or
dihydropyridine calcium channel blockers) will be discontinued, patients will be stratified
according to their urinary albumin excretion rate in normo- and micro-albuminuric and then
randomized to delapril alone (30 mg/day), delapril (30 mg/day) combined with manidipine (10
mg/day) or placebo given once daily in the morning for at least three years. During the
study, systolic and diastolic blood pressure in all treatments groups will be maintained ≤
120 and 80 mmHg respectively, with fixed doses of study treatments and flexible doses of
permitted antihypertensive therapy (diuretics, beta blockers, alfa blockers, centrally
acting adrenergic blockers. Blood pressure, blood glucose concentrations and urinary albumin
excretion rate will be monitored every three months. Serum lipid concentrations and GFR
(estimated with the iohexol plasma clearance) will be measured every six months.
Primary and Secondary Variables. The primary efficacy variable of this study is the rate of
GFR decline. The secondary efficacy variable will be the incidence of major cardiovascular
events (acute myocardial infarction, ictus or stroke, heart failure requiring
hospitalization, revascularization, amputation and cardiovascular mortality).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |